Diastolic blood pressure persistently >105mmHg post-IV thrombolysis despite antihypertensive intervention
10. Serious systemic hemorrhage in the past 30 days 11. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or
oral anticoagulant therapy with INR >1.5
12. Positive urine or serum pregnancy test for women of child bearing potential 13. Glucose <50 or >400 mg/dl 14. Platelets <100,000/mm3 15. Hematocrit <25 % 16. Elevated pre-thrombolysis PTT above laboratory upper limit of normal 17. Creatinine > 4 mg/dl 18. Ongoing renal dialysis, regardless of creatinine 19. Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in
full dose within the previous 24 hours
20. Abnormal PTT within 48 hours prior to randomization after receiving heparin or a
direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin)
21. Received Factor Xa inhibitors (such as Fondaparinaux, apixaban or rivaroxaban) within
the past 48 hours
22. Received glycoprotein IIb/IIIa inhibitors within the past 14 days 23. Pre-existing neurological or psychiatric disease which confounded the neurological or
functional evaluations e.g., baseline modified Rankin score >3
24. Other serious, advanced, or terminal illness or any other condition that the
investigator felt would pose a significant hazard to the patient if rt-PA, TNK, eptifibatide or argatroban therapy was initiated
- Example: known cirrhosis or clinically significant hepatic disease
- Current participation in another research drug treatment or interventional device trial - Subjects could not start another experimental agent until after 90 days
- Informed consent from the patient or the legally authorized representative was not or could not be obtained
- High density lesion consistent with hemorrhage of any degree
- Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT Scan. Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment